Spatial Multiomics Reveal Insights Into ADC Efficacy.

Area of Science:

• Oncology
• Molecular Biology
• Bioinformatics

Background:

• Antibody-drug conjugates (ADCs) show promise in solid tumor treatment but exhibit variable patient responses.
• Multiple ADC targets (e.g., NECTIN-4, HER2, TROP2) are under investigation for metastatic urothelial cancer.
• Predicting treatment efficacy and toxicity remains a challenge in ADC therapy.

Purpose of the Study:

• To review the utility of spatial multiomics in understanding ADC mechanisms and resistance.
• To highlight advancements in spatial transcriptomics and proteomics for ADC research.
• To propose an integrated framework for patient stratification and therapy development using spatial data.

Main Methods:

• Spatial multiomics integrates high-plex RNA sequencing and multiplex protein imaging with spatial coordinates.
• Analysis correlates ADC antigen expression, cell states, and tissue microenvironment with treatment outcomes.
• Machine learning and deep learning approaches are applied to spatial data for predictive analytics.

Main Results:

• Spatial multiomics provides direct correlation between molecular profiles, tissue architecture, and ADC response.
• Technological advancements enable detailed analysis of ADC action and resistance mechanisms.
• The framework facilitates patient stratification and prediction of on-/off-target toxicities.

Conclusions:

• Spatial multiomics is crucial for decoding ADC efficacy and resistance in solid tumors, especially metastatic urothelial cancer.
• Integrating spatial data with AI-driven analytics can personalize ADC treatment strategies.
• This approach can guide the design of next-generation ADCs and combination therapies.